Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...

The use of systemic radioactive medications as cancer therapies dates back to the 1940s when radioactive iodine was employed ...

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales. For Massachusetts ...

Plus now has $23 million in active awards support for the Company’s targeted radiotherapeutic pipeline Funding for pediatric ...

ChemoRad NP is a biodegradable, biocompatible NP capable of delivering both chemotherapeutics and radiotherapeutics efficiently. Using prostate cancer as a disease model, we demonstrated the ...

including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others. For more information, please visit www.omniab.com.

including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others. For more information, please visit www.omniab.com.

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing ...

About Plus Therapeutics Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with ...